FDA Grants Approval to Atezolizumab for Alveolar Soft Part Sarcoma
On December 9, 2022, the Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, Genentech, Inc.)
Yosef
December 17, 2022
On December 9, 2022, the Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, Genentech, Inc.)
Dear ASPS community, please read the recent update of this clinical trial from September 2020:
The American Society of Clinical Oncology (ASCO) annual meeting took place this year in Chicago
Below are summaries of three clinical studies and one preclinical study on Alveolar Soft Part
OPEN NOW: APROMISS – A Phase III Study of AL3818 (Anlotinib) Hydrochloride Monotherapy in Subjects
A presentation is the recent annual meeting of the American Society of Clinical Oncology (ASCO)
New clinical trial for ASPS is expected to open on March 2016. Study number: NCT02636725
OPEN NOW: CASPS – A Phase II Trial of Cediranib in the Treatment of Patients
The summary of the phase 2 clinical trial of Cediranib on Alveolar Soft Part Sarcoma
If you consider to join the following clinical trial: Sunitinib or Cediranib for Alveolar Soft
Designed with ❤️ by Studio Luxmeo | Developed by Yoav Levavi